Rheumatologist Steven Mendelsohn, MD, agreed to pay $549,554 to resolve allegations under the False Claims Act, according to a Jan. 28 news release from the U.S. Attorney’s Office.
What happened?
- In 2019, Dr. Mendelsohn allegedly submitted reimbursement claims to Medicare for intravenous immunosuppressive arthritis drugs that were not approved by the FDA for marketing and distribution in the U.S.
- The drugs were allegedly purchased from unauthorized distributors and intended for foreign markets.
- The settlement resolves civil allegations only.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.